Key result
Pharmacological manipulation of L-type Ca2+ channels modulated basal and catecholamine-stimulated lipolysis in rat white adipocytes, suggesting CaV1.2 as a potential therapeutic target for obesity.
Why the study?
L-type channel antagonists provide therapeutic benefit in hyperlipidaemia and insulin resistance, but the identity of L-type voltage-gated Ca2+ channels in white fat adipocytes and their effects on intracellular Ca2+, lipolysis, and lipogenesis were unknown.
White adipocytes possess constitutively active L-type Ca2+ channels (CaV1.2 and CaV1.3) that regulate lipolysis, suggesting CaV1.2 as a potential therapeutic target for obesity.
Answers are grounded in this paper and cite their sources.
May guide metabolic therapy development; leaves open translation from rat adipocyte data to human use.
L-type channel antagonists are of therapeutic benefit in the treatment of hyperlipidaemia and insulin resistance. Our aim was to identify L-type voltage-gated Ca2+ channels in white fat adipocytes, and determine if they affect intracellular Ca2+, lipolysis and lipogenesis. We used a multidisciplinary approach of molecular biology, confocal microscopy, Ca2+ imaging and metabolic assays to explore this problem using adipocytes isolated from adult rat epididymal fat pads. CaV1.2, CaV1.3 and CaV1.1 alpha1, beta and alpha2delta subunits were detected at the gene expression level. The CaV1.2 and CaV1.3 alpha1 subunits were identified in the plasma membrane at the protein level. Confocal microscopy with fluorescent antibodies labelled CaV1.2 in the plasma membrane. Ca2+ imaging revealed that the intracellular Ca2+ concentration, [Ca2 +]i was reversibly decreased by removal of extracellular Ca2+, an effect mimicked by verapamil, nifedipine and Co2+, all blockers of L-type channels, whereas the Ca2+ channel agonist BAY-K8644 increased [Ca2+]i. The finding that the magnitude of these effects correlated with basal [Ca2+]i suggests that adipocyte [Ca2+]i is controlled by L-type Ca2+ channels that are constitutively active at the adipocyte depolarized membrane potential. Pharmacological manipulation of L-type channel activity modulated both basal and catecholamine-stimulated lipolysis but not insulin-induced glucose uptake or lipogenesis. We conclude that white adipocytes have constitutively active L-type Ca2+ channels which explains their sensitivity of lipolysis to Ca2+ channel modulators. Our data suggest CaV1.2 as a potential novel therapeutic target in the treatment of obesity.
No takes yet. Share an insight, caveat, or question.
Fedorenko et al. (2019) studied this question. L-type channel modulators (verapamil, nifedipine, Co2+, BAY-K8644) was evaluated on Intracellular Ca2+ concentration, lipolysis, and lipogenesis. Pharmacological manipulation of L-type Ca2+ channels modulated basal and catecholamine-stimulated lipolysis in rat white adipocytes, suggesting CaV1.2 as a potential therapeutic target for obesity.
Synapse has enriched 10 related papers. Consider them for comparative context: